Literature DB >> 30056294

Appropriateness of non-vitamin K antagonist oral anticoagulant dose in patients with atrial fibrillation in Israel: A population-based study.

Martin H Ellis1, Sari Greenberg Dotan2, Ariel Hammerman2, Erez Battat2, Estela Derazne3, Orly Avnery4.   

Abstract

Entities:  

Keywords:  Atrial fibrillation; NOAC dose; Population study

Mesh：

Substances：

Year:  2018        PMID： 30056294     DOI： 10.1016/j.thromres.2018.07.024

Source DB:  PubMed          Journal:  Thromb Res        ISSN： 0049-3848            Impact factor:   3.944


× No keyword cloud information.
  3 in total

1.  Starting dose and dose adjustment of non-vitamin K antagonist oral anticoagulation agents in a nationwide cohort of patients with atrial fibrillation.

Authors:  A Di Lenarda; D Gabrielli; F Trotta; L Gozzo; F Mammarella; P P Olimpieri; A Cirilli; M Cuomo; M M Gulizia; F Colivicchi; G Murri; S K Kunutsor
Journal:  Sci Rep       Date:  2021-10-19       Impact factor: 4.379

2.  Off-label reduced-dose apixaban does not reduce hemorrhagic risk in Taiwanese patients with nonvalvular atrial fibrillation: A retrospective, observational study.

Authors:  I-Chih Chen; Wei-Ting Chang; Po-Chao Hsu; Ya-Lan Yeh; Syuan Zheng; Yuan-Chi Huang; Chih-Hsien Lin; Liang-Miin Tsai; Li-Jen Lin; Ping-Yen Liu; Yen-Wen Liu
Journal:  Medicine (Baltimore)       Date:  2021-06-11       Impact factor: 1.817

3.  Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK.

Authors:  Luis Alberto García Rodríguez; Mar Martín-Pérez; Pareen Vora; Luke Roberts; Yanina Balabanova; Gunnar Brobert; Samuel Fatoba; Kiliana Suzart-Woischnik; Bernhard Schaefer; Ana Ruigomez
Journal:  BMJ Open       Date:  2019-09-20       Impact factor: 2.692
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.